Literature DB >> 29338921

Faster progression from MCI to probable AD for carriers of a single-nucleotide polymorphism associated with type 2 diabetes.

Hugo Girard1, Olivier Potvin2, Scott Nugent2, Caroline Dallaire-Théroux3, Stephen Cunnane4, Simon Duchesne5.   

Abstract

Sporadic Alzheimer's disease (AD), as opposed to its autosomal dominant form, is likely caused by a complex interaction of genetic, environmental, and health lifestyle factors. Twin studies indicate that sporadic AD heritability could be between 58% and 79%, around half of which is explained by the ε4 allele of the apolipoprotein E (APOE4). We hypothesized that genes associated with known risk factors for AD, namely hypertension, hypercholesterolemia, obesity, diabetes, and cardiovascular disease, would contribute significantly to the remaining heritability. We analyzed 22 AD-associated single-nucleotide polymorphisms (SNPs), associated with these risk factors, that were included in the sequencing data of the Alzheimer's Disease Neuroimaging Initiative 1 data set, which included 355 participants with mild cognitive impairment (MCI). We built survival models with the selected SNPs to predict progression of MCI to probable AD over the 10-year follow-up of the study. The rs391300 SNP, located on the serine racemase (SRR) gene and linked to increased susceptibility to type 2 diabetes, was associated with progression from MCI to probable AD.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Genotype; Mild cognitive impairment; SRR gene; Type 2 diabetes; rs391300

Mesh:

Substances:

Year:  2017        PMID: 29338921     DOI: 10.1016/j.neurobiolaging.2017.11.013

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  8 in total

1.  Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET.

Authors:  Renaud La Joie; Adrienne V Visani; Suzanne L Baker; Jesse A Brown; Viktoriya Bourakova; Jungho Cha; Kiran Chaudhary; Lauren Edwards; Leonardo Iaccarino; Mustafa Janabi; Orit H Lesman-Segev; Zachary A Miller; David C Perry; James P O'Neil; Julie Pham; Julio C Rojas; Howard J Rosen; William W Seeley; Richard M Tsai; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal:  Sci Transl Med       Date:  2020-01-01       Impact factor: 17.956

Review 2.  The Potential of 'Omics to Link Lipid Metabolism and Genetic and Comorbidity Risk Factors of Alzheimer's Disease in African Americans.

Authors:  Kaitlyn E Stepler; Renã A S Robinson
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

3.  Integrated identification of key genes and pathways in Alzheimer's disease via comprehensive bioinformatical analyses.

Authors:  Tingting Yan; Feng Ding; Yan Zhao
Journal:  Hereditas       Date:  2019-07-16       Impact factor: 3.271

Review 4.  Genetic Variants behind Cardiovascular Diseases and Dementia.

Authors:  Wei-Min Ho; Yah-Yuan Wu; Yi-Chun Chen
Journal:  Genes (Basel)       Date:  2020-12-18       Impact factor: 4.096

5.  Prediction value of the genetic risk of type 2 diabetes on the amnestic mild cognitive impairment conversion to Alzheimer's disease.

Authors:  Jiayang Yang; Zirui Wang; Yumeng Fu; Jiayuan Xu; Yang Zhang; Wen Qin; Quan Zhang
Journal:  Front Aging Neurosci       Date:  2022-09-15       Impact factor: 5.702

6.  Relationship Between Alzheimer's Disease and the Immune System: A Meta-Analysis of Differentially Expressed Genes.

Authors:  Nan Wang; Ying Zhang; Li Xu; Shuilin Jin
Journal:  Front Neurosci       Date:  2019-01-17       Impact factor: 4.677

7.  Associating Type 2 Diabetes Risk Factor Genes and FDG-PET Brain Metabolism in Normal Aging and Alzheimer's Disease.

Authors:  Scott Nugent; Olivier Potvin; Stephen C Cunnane; Ting-Huei Chen; Simon Duchesne
Journal:  Front Aging Neurosci       Date:  2020-10-30       Impact factor: 5.750

Review 8.  A review of the mechanisms underlying selected comorbidities in Alzheimer's disease.

Authors:  Karolina Maciejewska; Kamila Czarnecka; Paweł Szymański
Journal:  Pharmacol Rep       Date:  2021-06-13       Impact factor: 3.024

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.